RT Journal Article SR Electronic T1 Randomised trial of cord clamping at very preterm birth: outcomes at 2 years JF Archives of Disease in Childhood - Fetal and Neonatal Edition JO Arch Dis Child Fetal Neonatal Ed FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health SP fetalneonatal-2019-316912 DO 10.1136/archdischild-2019-316912 A1 Lindsay Armstrong-Buisseret A1 Katie Powers A1 Jon Dorling A1 Lucy Bradshaw A1 Samantha Johnson A1 Eleanor Mitchell A1 Lelia Duley YR 2019 UL http://fn.bmj.com/content/early/2019/08/01/archdischild-2019-316912.abstract AB Objective To report outcomes at 2 years corrected age for children of women recruited to a trial comparing alternative policies for timing of cord clamping and immediate neonatal care at very preterm birth.Design Parallel group randomised (1:1) trial.Setting Eight UK tertiary maternity units.Participants Two hundred and seventy-six babies born to 261 women expected to have a live birth before 32+0 weeks’ gestation.Interventions Deferred cord clamping (≥2 min) and immediate neonatal care with cord intact or immediate (≤20 s) clamping and immediate neonatal care after clamping.Main outcome measure Composite of death or adverse neurodevelopmental outcome at 2 years corrected age.Results Six babies born after 35+6 weeks were excluded. At 2 years corrected age, outcome data were not available for a further 52 children, leaving 218 for analysis (115 deferred clamping, 103 immediate clamping). Overall, 24/115 (21%) children allocated deferred clamping died or had an adverse neurodevelopmental outcome compared with 35/103 (34%) allocated immediate clamping; risk ratio (RR) 0.61 (95% CI 0.39 to 0.96); risk difference (RD) −13% (95% CI −25% to −1%). Multiple imputation for missing data gave an RR 0.69 (95% CI 0.44 to 1.09) and RD −9% (95% CI −21% to 2%).Conclusions Deferred clamping and immediate neonatal care with cord intact may reduce the risk of death or adverse neurodevelopmental outcome at 2 years of age for children born very premature. Confirmation in larger studies is needed to determine the real benefits and harms.Trial registration number ISRCTN21456601.